3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Phase 1
1
Status
Active not recruiting
3
Recruiting
1
Sponsor Class
INDUSTRY
3
OTHER
1
Study Type
Interventional
4
Sponsor
Cancer Type
Thoracic
4
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Lung Neoplasms
2
Carcinoma, Renal Cell
2
Adenocarcinoma Of Esophagus
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Lung Diseases
1
Kidney Neoplasms
1
Esophageal Neoplasms
1
Erythrocytosis, Familial, 4
1
Cholangiocarcinoma
1
Advanced Non-Small Cell Lung Cancer
1
Interventions
pembrolizumab
55
Carboplatin
55
Pemetrexed
47
Cisplatin
37
Paclitaxel
21
Nivolumab
20
Docetaxel
19
durvalumab
18
osimertinib
14
Gemcitabine
14
Cetuximab
14
130-nm albumin-bound paclitaxel
14
atezolizumab
12
Specimen Handling
12
Magnetic Resonance Spectroscopy
12
amivantamab
10
Radiotherapy
8
lazertinib
7
Taxes
7
Radiosurgery
7
alectinib
6
Ramucirumab
6
Observation
6
Ipilimumab
6
Bevacizumab
6
cemiplimab
5
Leucovorin
5
Fluorouracil
5
zimberelimab
4
entrectinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
zimberelimab
×
30 days
×
Clear all
NCT05891171
2026-06-05
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled
NCT04736173
2026-06-01
ARC-10
Arcus Biosciences, Inc.
Phase 2
Active not recruiting
169 enrolled
NCT05633667
2026-06-01
VELOCITY-Lung
Gilead Sciences
Phase 2
Active not recruiting
192 enrolled
NCT06431633
2026-05-18
ARIAN
Fundación GECP
Phase 3
Recruiting
129 enrolled